



5.8 billion
patient treatment days
With EU approved biosimilar
medicines since 2006



+25,000 more UK
patients with moderate
Rheumatoid arthritis get
**access to biologic
therapy** thanks to
biosimilar competition



€50 billion
cumulative savings
using biosimilar medicines
between 2006-2023
€10 billion
in 2023 alone



A growing opportunity
for patients with over
**110 new biologic
medicines** opening to
biosimilar competition
by 2032



A considerable opportunity
for European healthcare
budget: a **\$53.5BN**
market will **open to
competition** between
2024-2032



By 2028
biosimilars impact
will be **>50%**
of the off-patent
competition in Europe



Biosimilar medicines
opportunity remains
largely untapped with only
14% volume share
of the accessible market
in Europe



Europe remains the
global leader with
over **50%** of the
biosimilar utilisation

**5.8 billion
patient treatment days**

With EU approved biosimilar
medicines since 2006



Source: IQVIA Spotlight on Biosimilars in Europe 2021

+25,000 more UK patients
with moderate Rheumatoid arthritis
get access to biologic therapy
thanks to biosimilar competition



Source: NICE UK 2021

A growing opportunity for patients with over **110** new **biologic medicines** opening to biosimilar competition by 2032




Source: IQVIA Biosimilars Competition in Europe 2020

A considerable opportunity for
European healthcare budget:
a **\$53.5BN** market will
open to competition
2024-2032




Source: IQVIA Biosimilars Competition in Europe 2020

By 2028
biosimilars impact
will be **>50%**
of the off-patent
competition in Europe




Source: filling the gap https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines_4b2e9cb9-en

Biosimilar medicines opportunity remains largely untapped with only **14% volume share** of the accessible market in Europe



Source: IQVIA MIDAS® Q4 2020, IQVIA ForecastLink data for post-2020 period, Rx biologics in 23 European markets

Europe remains the global leader
with over **50%** of the
biosimilar utilisation



Source: IQVIA MIDAS MAT Q1 2021; Rx-only. Figures are in Thousands of USD at Constant Exchange Rate